These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8480475)

  • 1. Influence of short-term dexfenfluramine therapy on glucose and lipid metabolism in obese non-diabetic patients.
    Andersen PH; Richelsen B; Bak J; Schmitz O; Sørensen NS; Lavielle R; Pedersen O
    Acta Endocrinol (Copenh); 1993 Mar; 128(3):251-8. PubMed ID: 8480475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic indices in relation to body composition changes during weight loss on Dexfenfluramine in obese women from two South African ethnic groups.
    van der Merwe MT; Wing JR; Celgow LH; Gray IP; Lönn L; Joffe BI; Lönnroth PN
    Int J Obes Relat Metab Disord; 1996 Aug; 20(8):768-76. PubMed ID: 8856402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors.
    Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS
    Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein metabolism in human obesity: relationship with glucose and lipid metabolism and with visceral adipose tissue.
    Solini A; Bonora E; Bonadonna R; Castellino P; DeFronzo RA
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2552-8. PubMed ID: 9253333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and chronic effects of dexfenfluramine on glucose and insulin response to intravenous glucose in diabetic and non-diabetic obese subjects.
    Glaser B; Raveh Y; Norynberg C; Berry E; Lavielle R; Nathan C; Cerasi E
    Diabetes Res; 1992; 19(4):165-76. PubMed ID: 1343113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site of insulin resistance in type 1 diabetes: insulin-mediated glucose disposal in vivo in relation to insulin binding and action in adipocytes in vitro.
    Yki-Järvinen H; Taskinen MR; Kiviluoto T; Hilden H; Helve E; Koivisto VA; Nikkilä EA
    J Clin Endocrinol Metab; 1984 Dec; 59(6):1183-92. PubMed ID: 6490795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.
    Bugianesi E; Gastaldelli A; Vanni E; Gambino R; Cassader M; Baldi S; Ponti V; Pagano G; Ferrannini E; Rizzetto M
    Diabetologia; 2005 Apr; 48(4):634-42. PubMed ID: 15747110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.
    Henriksen JE; Levin K; Thye-Rønn P; Alford F; Hother-Nielsen O; Holst JJ; Beck-Nielsen H
    Diabetes; 2000 Jul; 49(7):1209-18. PubMed ID: 10909980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dexfenfluramine treatment on body weight and postprandial thermogenesis in obese subjects. A double-blind placebo-controlled study.
    Lafreniere F; Lambert J; Rasio E; Serri O
    Int J Obes Relat Metab Disord; 1993 Jan; 17(1):25-30. PubMed ID: 8383638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.
    Scheen AJ; Paolisso G; Salvatore T; Lefèbvre PJ
    Diabetes Care; 1991 Apr; 14(4):325-32. PubMed ID: 2060435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmented effect of short-term pulsatile versus continuous insulin delivery on lipid metabolism but similar effect on whole-body glucose metabolism in obese subjects.
    Schmitz O; Pedersen SB; Mengel A; Pørksen N; Bak J; Møller N; Richelsen B; Alberti KG; Butler PC; Orskov H
    Metabolism; 1994 Jul; 43(7):842-6. PubMed ID: 7913205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity.
    Ditschuneit HH; Flechtner-Mors M; Adler G
    J Cardiovasc Risk; 1996 Aug; 3(4):397-403. PubMed ID: 8946272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension.
    Bonora E; Bonadonna RC; Del Prato S; Gulli G; Solini A; Matsuda M; DeFronzo RA
    Diabetes; 1993 May; 42(5):764-72. PubMed ID: 8482434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes.
    Hother-Nielsen O; Schmitz O; Andersen PH; Beck-Nielsen H; Pedersen O
    Acta Endocrinol (Copenh); 1989 Mar; 120(3):257-65. PubMed ID: 2648723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women.
    Flechtner-Mors M; Ditschuneit HH; Yip I; Adler G
    Am J Clin Nutr; 1998 Apr; 67(4):611-5. PubMed ID: 9537607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type II) diabetic patients.
    Paolisso G; Scheen A; Cozzolino D; Di Maro G; Varricchio M; D'Onofrio F; Lefebvre PJ
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1510-4. PubMed ID: 8200955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
    DeFronzo RA; Barzilai N; Simonson DC
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1294-301. PubMed ID: 1955512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin.
    Jazet IM; Pijl H; Frölich M; Romijn JA; Meinders AE
    Metabolism; 2005 Jun; 54(6):705-12. PubMed ID: 15931603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.